WO2015026112A1 - 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 혈액암 또는 암전이 억제용 조성물 - Google Patents
모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 혈액암 또는 암전이 억제용 조성물 Download PDFInfo
- Publication number
- WO2015026112A1 WO2015026112A1 PCT/KR2014/007620 KR2014007620W WO2015026112A1 WO 2015026112 A1 WO2015026112 A1 WO 2015026112A1 KR 2014007620 W KR2014007620 W KR 2014007620W WO 2015026112 A1 WO2015026112 A1 WO 2015026112A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- palmitoyl
- cancer
- oleoyl
- stearoyl
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 206010027476 Metastases Diseases 0.000 title claims abstract description 39
- 201000005787 hematologic cancer Diseases 0.000 title claims abstract description 39
- 230000009401 metastasis Effects 0.000 title claims abstract description 38
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 title claims abstract description 34
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 26
- 239000004480 active ingredient Substances 0.000 title claims abstract description 10
- 102000004388 Interleukin-4 Human genes 0.000 claims abstract description 39
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 39
- 230000000694 effects Effects 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 76
- 201000011510 cancer Diseases 0.000 claims description 59
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 32
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 125000005645 linoleyl group Chemical group 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 11
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 9
- 210000003056 antler Anatomy 0.000 claims description 8
- 125000005313 fatty acid group Chemical group 0.000 claims description 8
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 7
- 125000002714 alpha-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 206010000830 Acute leukaemia Diseases 0.000 claims description 4
- -1 Arachidonoyl (arachidonoyl) Chemical group 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000024207 chronic leukemia Diseases 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000003440 toxic substance Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 55
- 229940028885 interleukin-4 Drugs 0.000 description 36
- 238000011282 treatment Methods 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 3
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 3
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002257 antimetastatic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003547 immunosorbent Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000002886 arachidonoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000006491 bone marrow cancer Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IGUZJYCAXLYZEE-UHFFFAOYSA-N 3,4,5-trihydroxypentan-2-one Chemical compound CC(=O)C(O)C(O)CO IGUZJYCAXLYZEE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- CFXGEYBOJLADPT-ATHFLDRKSA-N C(CCCCCCCCCCCCCCC)(=O)OC(C(OCCCCCCCC\C=C/C\C=C/CCCCC)COC(C)=O)C(CCCCCCC\C=C/C\C=C/CCCCC)=O Chemical compound C(CCCCCCCCCCCCCCC)(=O)OC(C(OCCCCCCCC\C=C/C\C=C/CCCCC)COC(C)=O)C(CCCCCCC\C=C/C\C=C/CCCCC)=O CFXGEYBOJLADPT-ATHFLDRKSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 238000003725 ONE-Glo Luciferase Assay System Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
Definitions
- the present invention relates to a composition for inhibiting blood cancer or cancer metastasis and its use containing a monoacetyldiacylglycerol compound as an active ingredient.
- Cancer is a group of abnormal cells caused by continuous division and proliferation due to the disruption of the balance between cell division and death due to various causes, also called a tumor. It usually affects more than 100 different parts of the body, including organs, white blood cells, bones, lymph nodes, etc., and develops into severe symptoms through infiltration into surrounding tissues and metastases to other organs.
- the causes of cancer include environmental or external factors such as chemicals, viruses, bacteria, ionizing radiation, and internal factors such as congenital gene mutations. Recently, the association between chronic inflammation and cancer occurrence has emerged, and a lot of data supporting this has been reported. Infections and chronic inflammation account for 25% of all cancers and are known to be at much higher risk for cancer in patients with chronic inflammation and reactive oxygen species.
- mediators that control the inflammatory response such as cytokines, free radicals, and growth factors, induce genetic and epigenetic changes such as mutations in tumor suppressor genes, DNA methylation, and post-transcriptional modifications, resulting in normal cell homeostasis. It is believed to change the pathways necessary to maintain the disease, and further develop and advance cancer.
- EC-18 is a type of monoacetyletyldiglyceride, isolated from antler. EC-18 has been shown to significantly increase the survival rate of animals in sepsis animal models using cecal-ligation-puncture, and is not toxic in good laboratory practice (GLP) toxicity studies. However, it is not yet disclosed what effect such a monoacetyldiacylglycerol compound including EC-18 will have on blood cancer or cancer metastasis. Accordingly, the present inventors have made intensive efforts to develop blood cancer or cancer metastasis inhibitors of natural compounds or new compounds. As a result, the monoacetyldiacylglycerol compound inhibits the secretion of IL-4 and also inhibits the activity of STAT-6. By destroying the microenvironment for the growth of tissues, it was confirmed that the prevention, treatment or prevention of cancer of blood cancer can be usefully used to complete the present invention.
- One object of the present invention is to provide a pharmaceutical composition and health functional food composition for inhibiting blood cancer or cancer metastasis, containing a monoacetyl-diacylglycerol compound represented by the following formula (1) as an active ingredient.
- R1 and R2 are each a fatty acid group having 14 to 20 carbon atoms.
- Another object of the present invention a method for preventing or treating blood cancer, or a method for inhibiting cancer metastasis, comprising administering the pharmaceutical composition to a subject having or possibly suffering from or developing a cancer of blood cancer.
- a pharmaceutical composition for inhibiting blood cancer or cancer metastasis containing a monoacetyldiacylglycerol compound represented by the following formula (1) as an active ingredient.
- R1 and R2 are each a fatty acid group having 14 to 20 carbon atoms.
- the fatty acid group refers to the remainder of which the -OH group is excluded from the carboxyl group of the fatty acid.
- the pharmaceutical composition for inhibiting blood cancer or cancer metastasis of the present invention may include a monoacetyldiacylglycerol compound represented by Chemical Formula 1.
- a monoacetyldiacylglycerol compound represented by Chemical Formula 1.
- the term "monoacetyldiacylglycerol compound” refers to a derivative of glycerol having one acetyl group and two acyl groups, also referred to as monoacetyldiglycerol (MADG).
- R1 and R2 may each be a fatty acid group having 14 to 20 carbon atoms, preferably palmitoyl, oleoyl, linoleoyl, Linolenoyl, stearoyl, myristoyl, or arachidonoyl, and the like may be, but are not limited thereto.
- R1 and R2 is oleoyl / palmitoyl, palmitoyl / oleoyl, palmitoyl / linoleyl, palmitoyl / linolenoyl, palmitoyl / arachidonoyl, palmi Soil / Stearoyl, Palmitoyl / Palmitoyl, Oleoyl / Stearoyl, Linoleoyl / Palmitoyl, Linoleoyl / Stearoyl, Stearoyl / Linooleyl, Stearoyl / Oleoyl, Miri It may be, but is not limited to, stolen / linoleoyl or myristoyl / oleoyl.
- the monoacetyldiacylglycerol compound may be (R) -type, (S) -type or racemate in optical
- the monoacetyldiacylglycerol compound may be preferably a compound represented by the following formula (2).
- the compound represented by the formula (2) is called 1-palmitoyl-2-linoleyl (linoleoyl) -3-acetylglycerol (acetylglycerol), may also be named EC-18.
- R1 and R2 of the compound correspond to palmitoyl and linoleyl, respectively.
- the monoacetyldiacylglycerol compound may be extracted / separated from antler, or may be prepared by a known organic synthesis method (Korea Patent No. 10-0789323). Specifically, the antler is extracted with hexane, the extraction residue is extracted again with chloroform, and the obtained extract is distilled under reduced pressure to obtain the chloroform extract of the antler.
- the amount of hexane and chloroform, which are the extraction solvents used in the extraction, is sufficient to cover the amount of deer antler used, and in general, hexane and chloroform may be used in a ratio of about 4 to 5 L with respect to 1 kg of deer antler, respectively. The type and amount of use is not limited to this.
- the chloroform extract of antler obtained in this manner was subsequently fractionated and purified by a series of silica gel column chromatography and TLC method to obtain the monoacetyldiacylglycerol compound used in the present invention.
- Chloroform / methanol, hexane / ethyl acetate, hexane / ethyl acetate / acetic acid, etc. may be used as the eluent in the chromatography purification step, but is not limited thereto.
- a method for chemically synthesizing the monoacetyldiacylglycerol compound used in the present invention is disclosed in Korean Patent No. 10-0789323. Specifically, (a) attaching a protecting group at position 3 of 1-R1-glycerol to prepare 1-R1-3-protecting group-glycerol; (b) preparing 1-R1-2-R2-3-protecting group-glycerol by introducing an R2 group at position 2 of 1-R1-3-protecting group-glycerol; (c) a step of simultaneously performing the deprotection reaction and the acetylation reaction of 1-R1-2-R2-3-protecting group-glycerol, and purifying as needed, and the desired monoacetyldiacylglycerol compound It may be synthesized, and may be obtained by other method of acetic acid decomposition (phosphatodylcholine), but is not limited thereto. All stereoisomers of the compound of Formula 1 may also be included within the scope of the present invention.
- the monoacetyldiacylglycerol compound can reduce the secretion of IL-4, thereby confirming that it can be effectively used for inhibiting blood cancer or metastasis.
- cancer refers to a state in which a problem arises in the regulation function of the cell itself, and abnormal cells that normally need to die excessively proliferate and invade surrounding tissues and organs to form agglomerates and destroy or modify existing structures. It is used in the same sense as a malignant tumor.
- anticancer in the present invention means any activity that inhibits the proliferation of cancer cells or kills cancer cells.
- hematologic cancer may be selected from the group consisting of lymphoma, acute leukemia, chronic leukemia, and multiple myeloma, but is not limited thereto.
- cancer metastasis means, but is not limited to, cancer cells, particularly cancer cells related to blood cancer, spread from one organ or part thereof to another organ or organ periphery.
- malignant cancer cells have the ability to metastasize, and cancer cells escape from the primary cancer, penetrate into the lymphatic or vascular system, circulate blood vessels, and grow in normal tissue in other parts of the body.
- Cancer metastasis is a hallmark of malignant cancer, which accounts for 90% of cancer deaths. Therefore, in the present invention, cancer metastasis suppression may be used to mean that cancer cells spread to other organs or peripheral parts.
- prevention means any action that inhibits or delays cancer or cancer metastasis by administration of the composition of the present invention
- treatment means that the symptoms caused by cancer or cancer metastasis improve with the composition of the present invention. Means any action that is or is beneficially altered.
- Tumor-associated macrophage is a macrophage associated with tumor progression and metastasis, mainly found around tumors. Improving the tumor microenvironment by attacking these macrophages by immunizing molecules overexpressed by tumor-associated macrophages has emerged as a new method of anticancer.
- Tumor-associated macrophages are macrophages of the M2 phenotype, and these are known to be mainly induced by Th2 cytokines such as IL-4 and IL-13. In fact, these macrophages are known to contain angiogenesis factors and metalloproteinases. Secrete and participate in signaling pathways that regulate the action of fibroblasts in the tumor stroma to promote tumor cell proliferation and metastasis.
- IL-4 refers to cytokines having various immunomodulatory functions secreted from Th2 lymphocytes, eosinophils, mast cells, and the like. IL-4 is found at higher concentrations than normal tissue in several cancer tissues, and it has been reported that large amounts of IL-4 are produced in tumor-infiltrating lymphocytes (TILs). In particular, IL-4 is known as a representative cytokine to activate tumor-associated macrophages. Thus, IL-4 induces the activity of M2 phenotype macrophages, thereby inducing tumor growth, metastasis, angiogenesis and the like.
- TILs tumor-infiltrating lymphocytes
- the monoacetyldiacylglycerol compound can inhibit the activity of STAT-6, and thus it can be effectively used for inhibiting blood cancer or cancer metastasis.
- STAT-6 is a transcription factor and is known to play an important role in carrying out an IL-4 mediated biological response. That is, STAT-6 is activated in phosphorylated form by IL-4, followed by the IL-4 / STAT-6 signaling pathway. The signaling pathway is widely known to play an important role in resistance to cell proliferation / growth and apoptosis. Therefore, inhibition of STAT-6 has the effect of inducing apoptosis and inhibiting cancer metastasis, and by destroying the microenvironment for the growth of cancer tissue, it can have an effect as an effective therapeutic and therapeutic combination of the tumor.
- the tumor volume was reduced statistically significantly compared to the negative control group, and the tumor weight was also statistically significantly smaller than the negative control group, so that EC-18 decreased the tumor growth. It was confirmed that inhibition (Experimental Example 4 Fig. 6, 7). This shows that the monoacetyldiacylglycerol compound is effective for preventing, treating or inhibiting cancer metastasis of blood cancer.
- compositions comprising the monoacetyldiacylglycerol compounds of the present invention may further comprise suitable carriers, excipients or diluents commonly used in the manufacture of pharmaceutical compositions.
- the content of the monoacetyldiacylglycerol compound included in the composition is not particularly limited, but 0.0001 to 100% by weight, preferably 0.01 to 50.0% by weight, more preferably 0.01% by weight based on the total weight of the composition. To 20 wt%.
- the pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilizers and suppositories. It can have a formulation of, and can be a variety of oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
- Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used.
- Liquid preparations for oral administration include suspensions, solution solutions, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
- base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- composition of the present invention may be administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type and severity, age, sex, disease of the individual. It may be determined according to the type, activity of the drug, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field.
- the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations.
- the preferred dosage of the composition of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration of time, and the suitable total daily dosage can be determined by the practitioner within the correct medical judgment. Generally, an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, may be administered once to several times daily.
- the composition is not particularly limited as long as it is an individual for the purpose of inhibiting blood cancer or metastasis, and any individual may be applied.
- it can be applied to any individual, such as monkeys, dogs, cats, rabbits, marmots, rats, mice, cows, sheep, pigs, goats, birds, and the like, and to any individual, and the mode of administration is conventional in the art. If it is method, it includes without limitation. For example, it may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.
- the present invention provides a health functional food composition for inhibiting blood cancer or cancer metastasis, containing a monoacetyldiacylglycerol compound represented by the following formula (1) as an active ingredient.
- R1 and R2 may each be a fatty acid group having 14 to 20 carbon atoms, but are not limited thereto.
- the monoacetyldiacylglycerol compound of the present invention or a pharmaceutically acceptable salt thereof may be included in the nutraceutical composition for the purpose of inhibiting blood cancer or cancer metastasis.
- the monoacetyldiacylglycerol compound, blood cancer, and cancer metastasis inhibition are as described above.
- the term "improvement" refers to any act that improves or benefits the suspicion of a cancer or cancer metastasis and the onset of a subject using the composition of the invention.
- the composition of the present invention When the composition of the present invention is used in a health functional food, the composition may be included as it is or used with other health functional foods or health functional food ingredients, and may be appropriately used according to a conventional method.
- the mixing amount of the active ingredient may be appropriately determined depending on the intended use.
- the composition of the present invention in the production of food or beverage may be included in an amount of preferably 15 parts by weight or less, more preferably 10 parts by weight or less with respect to the raw material.
- the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
- health functional food may include the composition of the present invention
- specific examples include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, and ice cream.
- Dairy products, various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc. may include all of the health functional foods in the conventional sense, and may include foods used as feed for animals.
- the health functional food composition of the present invention when used in the form of a beverage, it may contain various sweetening agents, flavoring agents or natural carbohydrates, etc. as additional ingredients, as in the usual beverage.
- the natural carbohydrate can be glucose, monosaccharides such as fructose, maltose, disaccharides such as sucrose, polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, erythritol.
- the ratio of the natural carbohydrate is not limited thereto, but may be preferably about 0.01 to 0.04 g, more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention.
- the sweetener may be a natural sweetener such as taumartin, stevia extract and a synthetic sweetener such as saccharin, aspartame.
- the nutraceutical composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents used in carbonated drinks, and the like. Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
- the present invention provides a method for preventing or treating blood cancer, or a method for inhibiting cancer metastasis, comprising administering the pharmaceutical composition to a suspicious subject of blood cancer or cancer metastasis.
- the suspicious subject of hematologic cancer or cancer metastasis refers to any animal including a human having or may develop the disease, and includes a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof.
- the term "administration" means introducing the pharmaceutical composition of the present invention to a subject suspected of having a blood cancer or cancer metastasis by any suitable method, and the route of administration is oral or parenteral as long as it can reach the target tissue. Administration can be via a variety of routes.
- the method of treatment of the present invention may include administering a pharmaceutical composition comprising the monoacetyldiacylglycerol compound of Formula 1 in a pharmaceutically effective amount.
- Suitable total daily doses may be determined by the practitioner within the correct medical judgment and are generally in amounts of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / The amount of kg may be administered once to several times daily.
- the specific therapeutically effective amount for a particular patient is determined by the specific composition, including the type and extent of the reaction to be achieved, whether or not other agents are used in some cases, the age, weight, general health of the patient, It is desirable to apply differently depending on various factors and similar factors well known in the medical field, including sex and diet, time of administration, route of administration and rate of composition, duration of treatment, drugs used with or co-specific with the specific composition.
- the monoacetyldiacylglycerol compound of the present invention has an excellent effect of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, overcoming the side effects of blood cancer or cancer metastasis inhibitors currently used, and without toxicity.
- a compound having excellent therapeutic effect it may be usefully used as a composition for preventing, treating and improving blood cancer or cancer metastasis.
- Figure 1 shows the effect of (A) phosphorylation inhibitory effect according to EC-18 concentration of STAT-6 phosphorylated by IL-4 and (B) EC-18 concentration of STAT-6 phosphorylated by IFN- ⁇ in U937 cells.
- Western blot results showing the inhibition of phosphorylation according to the star treatment.
- Figure 2 shows the Western blot results showing the phosphorylation inhibitory effect according to the EC-18 concentration of STAT-6 phosphorylated by IL-4 in A549 cells (A), U937 cells (B) and Jurkat cells (C) It is also.
- Figure 3 is a diagram showing the luminescence value of luciferase according to the EC-18 concentration treatment of STAT-6 activated by IL-4 and IFN- ⁇ activated in HEK293 cells and A549 cells.
- Figure 4 is a diagram observing the amount of transcription of IL-4 according to the concentration of EC-18 treatment in RBL-2H3 cells by enzyme-linked immunosorbent absorption analysis (ELISA).
- ELISA enzyme-linked immunosorbent absorption analysis
- FIG. 5 is a diagram showing the amount of IL-4 expression according to the treatment of EC-18 concentration in RBL-2H3 cells by time zone (6h, 15h and 24h).
- Figure 6 is a graph showing the results of the tumor volume reduction by treatment with EC-18 in a model animal transplanted with human blood cancer cells.
- Figure 7 is a graph showing the results of weight reduction of tumors by treatment with EC-18 in model animals transplanted with human hematological cancer cells.
- Figure 8 is a photograph showing the change in tumor size in the EC-18 administration group, negative control group and positive control group in blood cancer model mice.
- Cold SDS-soluble buffer [(50 mM HEPES, 150 mM NaCl, 0.2 mM EDTA, 0.5% NP-40, 0.1% SDS, 1 mM Na 3 VO 4) in cells treated with EC-18 and IL-4 and IFN- ⁇ , 10 mM NaF, and complete Protein Inhibitor Cocktail (Roche)] were dissolved in ice for 30 minutes, and the dissolved cell solution was spun at 13,000 rpm for 30 minutes using a high speed rotor to precipitate the insoluble portion and separate the aqueous solution.
- poly rabbit anti- (STAT1, STAT6) and -phosphor (STAT1, STAT6) were used as primary antibodies. The reaction was carried out at room temperature for 60 minutes. The secondary antibody was reacted with horseradish peroxidase peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology, USA) (1: 3000) at room temperature for 60 minutes. The same amount of cellular protein was measured by poly rabbit anti- (STAT1, STAT6).
- the membrane was reacted with an ECL reagent (Millipore, Billerica, Mass., USA) and exposed to an X-ray film to confirm the degree of phosphorylation of STAT as a band on the film.
- the p4xSTAT6-Luc2P vector (Addgene) containing the STAT-6 element to which STAT-6 binds was introduced into HEK293 cells and A549 cells, followed by EC-18 pretreatment and IL-4 treatment to activate STAT-6. Inhibition was analyzed. In addition, the activity of STAT-1 was analyzed using pGL4.45 [luc2P / ISRE / Hygro] vector (Promega) containing the Interferon Stimulated Response Element (ISRE) to which STAT-1 binds.
- IRE Interferon Stimulated Response Element
- HEK293 cells and A549 cells were separated by treatment with trypsin-EDTA, and then aliquoted in a culture dish, and p4xSTAT6-Luc2P and pGL4.45 [luc2P / ISRE / Hygro] vectors were introduced into the cells using an Attractene Transfection Reagent. , Incubated for one day at 5% CO 2 conditions. The next day, the cells were separated from the culture dish and then dispensed in a 0.1-well so that the population of 5 ⁇ 10 4 cells / well in a 96-well plate and incubated for one day at 37 °C, 5% CO 2 conditions.
- luciferase activation by IL-4 and IFN- ⁇ signal transduction was confirmed using the ONE-Glo Luciferase Assay System (Promega) as follows. Specifically, 0.1-well solution of ONE-Glo TM Luciferase Assay Buffer and Substrate mixed 1: 1 was added to 96-well and the light emitted after about 3 minutes was measured using VICTOR X Multilabel Plate Reader (PerkinElmer). It was measured for a second.
- the luminescence value of STAT-6 luciferase was decreased when EC-18 was treated for each concentration, compared to the IL-4 only treatment, and thus the relative activity was decreased.
- the emission value of STAT-1 luciferase was not changed by EC-18 (Fig. 3). That is, it was confirmed that the activity of STAT-6 induced by IL-4 was significantly decreased in HEK293 cells and A549 cells treated with EC-18.
- Amplification by PCR reaction was performed using GeneAmp PCR system 2700 (Applied Biosystems, Foster city, CA, USA) under the following conditions; After 25 to 40 cycles of 5 minutes at 94 °, followed by 45 seconds at 94 °, 45 seconds at 56 ° and 1 minute at 72 °, the final extension reaction was carried out at 72 ° for 7 minutes.
- Table 1 shows the primer sequences used for cDNA amplification by PCR. The following PCR primers were designed using the Primer3 program and were purchased from Bioneer (Korea, Daejeon).
- PCR products were separated on 1.5% agarose gel, stained with ethidium bromide (EtBr) and visualized with Gel Doc 2000 UV trans-illuminator (Bio-Rad Laboratories, Hercules, CA, USA), followed by Quantity One software (Bio-Rad Laboratories) was used for analysis. Each sample was tested three or more times and representative data were presented.
- EC-18 was prepared to be treated at a concentration of 0.1 pg / ml to 10 ⁇ g / ml for 1 hour to react, incubated at 37 ° C. for 18 hours after treatment with antigen, and then cells were removed to obtain supernatant.
- Quantification of mouse IL-4 present in cell culture medium of RBL-2H3 cells was carried out using enzyme-linked immunosorbent assay (enzyme-) according to the manufacturer's protocol using a commercially available monoclonal antibody (mAb) (BD Biosciences).
- mAb monoclonal antibody
- ELISA linked immunosorbent assay
- the growth inhibitory effect of tumors was evaluated after oral administration of EC-18, a test substance, to male nude mice implanted with RPMI 8226 cells, a bone marrow cancer cell line derived from the human body.
- the group consisted of negative control group, 500 mg / kg dose of test substance, 500 mg / kg dose of test substance and 80 mg / kg dose of positive control (gemcitabine, Gemcitabine) combination group, 500 mg / kg dose test
- a total of six groups of substance and 120 mg / kg dose of positive control group, 80 and 120 mg / kg dose of positive control group were composed of 10 groups.
- the negative control group was injected with olive oil as an excipient and the test substance administration group was forced to administer the test substance (EC-18) in the stomach once per day, 4 weeks, for a total of 28 times.
- the positive control group was gemcitabine as a positive control group.
- General symptoms were observed once daily during the observation period, and the body weight and tumor volume (mm 3 ) of the animals were measured twice / week. After the end of the observation period, the tumor was extracted and the weight (Tumor weight, g) was measured and shown in FIGS. 6 and 7, respectively.
- the test substance administration group of 500 mg / kg dose was statistically significantly inhibited compared to the negative control group
- the tumor weight was also statistically compared to the negative control group
- Significantly small measurements inhibited tumor growth.
- a picture showing the change in tumor size after administration to the EC-18 and gemcitabine positive control group in blood cancer model mice is shown in FIG. As shown in Figure 8, even when the EC-18 administration, it can be seen that the tumor size is reduced similarly to the positive control group.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Name | Forward primer | Reverse primer |
GAPDH | CCATCACCATCTTCCAGGAG(서열번호 1) | ACAGTCTTCTGGGTGGCAGT (서열번호 2) |
IL-4 | AATGGGTCTCACCTCCCAAC(서열번호 3) | TTCAGCTCGAACACTTTGAA (서열번호 4) |
Claims (15)
- 제1항에 있어서, 상기 R1 및 R2는 각각 팔미토일(palmitoyl), 올레오일(oleoyl), 리놀레오일(linoleoyl), 리놀레노일(linolenoyl), 스테아로일(stearoyl), 미리스토일(myristoyl), 아라키도노일(arachidonoyl)로 구성되는 군으로부터 선택되는 것인 조성물.
- 제1항에 있어서, 상기 R1 및 R2의 조합(R1/R2)은 올레오일/팔미토일, 팔미토일/올레오일, 팔미토일/리놀레오일, 팔미토일/리놀레노일, 팔미토일/아라키도노일, 팔미토일/스테아로일, 팔미토일/팔미토일, 올레오일/스테아로일, 리놀레오일/팔미토일, 리놀레오일/스테아로일, 스테아로일/리놀레오일, 스테아로일/올레오일, 미리스토일/리놀레오일, 미리스토일/올레오일로 구성되는 군으로부터 선택되는 것인 조성물.
- 제1항에 있어서, 상기 모노아세틸디아실글리세롤류 화합물은 녹용으로부터 분리된 것인 조성물.
- 제1항에 있어서, 상기 혈액암은 림프종, 급성 백혈병, 만성 백혈병, 및 다발성 골수종으로 이루어진 군에서 선택된 어느 하나인 항암 또는 암전이 억제용 조성물.
- 제1항에 있어서, 상기 모노아세틸디아실글리세롤 화합물은, IL-4의 분비를 억제하는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 모노아세틸디아실글리세롤 화합물은, STAT-6의 활성을 억제하는 것을 특징으로 하는 조성물.
- 제10항에 있어서, 상기 R1 및 R2는 각각 팔미토일(palmitoyl), 올레오일(oleoyl), 리놀레오일(linoleoyl), 리놀레노일(linolenoyl), 스테아로일(stearoyl), 미리스토일(myristoyl), 아라키도노일(arachidonoyl)로 구성되는 군으로부터 선택되는 것인 조성물.
- 제10항에 있어서, 상기 R1 및 R2의 조합(R1/R2)은 올레오일/팔미토일, 팔미토일/올레오일, 팔미토일/리놀레오일, 팔미토일/리놀레노일, 팔미토일/아라키도노일, 팔미토일/스테아로일, 팔미토일/팔미토일, 올레오일/스테아로일, 리놀레오일/팔미토일, 리놀레오일/스테아로일, 스테아로일/리놀레오일, 스테아로일/올레오일, 미리스토일/리놀레오일, 미리스토일/올레오일로 구성되는 군으로부터 선택되는 것인 조성물.
- 제10항에 있어서, 상기 혈액암은 림프종, 급성 백혈병, 만성 백혈병, 및 다발성 골수종으로 이루어진 군에서 선택된 어느 하나인 항암 또는 암전이 억제용 조성물.
- 제1항 내지 제9항 중 어느 한 항의 조성물을 비인간 개체에 투여하는 단계를 포함하는, 혈액암 또는 암전이의 예방 또는 치료방법.
- 제14항에 있어서, 상기 혈액암은 림프종, 급성 백혈병, 만성 백혈병, 및 다발성 골수종으로 이루어진 군에서 선택된 어느 하나인 항암 또는 암전이 억제용 조성물.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014309635A AU2014309635B2 (en) | 2013-08-19 | 2014-08-18 | Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer or metastasis |
EP14838256.7A EP3037092B1 (en) | 2013-08-19 | 2014-08-18 | Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer |
JP2016536021A JP6201054B2 (ja) | 2013-08-19 | 2014-08-18 | モノアセチルジアシルグリセロール化合物を有効成分として含有する血液癌または癌転移抑制用組成物 |
US14/912,916 US10058527B2 (en) | 2013-08-19 | 2014-08-18 | Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis |
CA2921841A CA2921841C (en) | 2013-08-19 | 2014-08-18 | Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer or metastasis |
ES14838256T ES2779047T3 (es) | 2013-08-19 | 2014-08-18 | Composición que contiene compuesto de monoacetil diglicéridos como ingrediente activo para inhibir el cáncer de sangre |
RU2016109986A RU2632098C2 (ru) | 2013-08-19 | 2014-08-18 | Композиция для подавления раковых заболеваний крови или метастазирования рака, содержащая в качестве активного ингредиента моноацетилдиглицеридное соединение |
CN201480055291.2A CN105792822B (zh) | 2013-08-19 | 2014-08-18 | 含有以单乙酰基二酰基甘油化合物作为有效成分的血癌或者癌转移抑制用组合物 |
US16/045,617 US10857119B2 (en) | 2013-08-19 | 2018-07-25 | Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis |
US16/886,280 US20200330421A1 (en) | 2013-08-19 | 2020-05-28 | Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130098185 | 2013-08-19 | ||
KR10-2013-0098185 | 2013-08-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/912,916 A-371-Of-International US10058527B2 (en) | 2013-08-19 | 2014-08-18 | Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis |
US16/045,617 Continuation US10857119B2 (en) | 2013-08-19 | 2018-07-25 | Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015026112A1 true WO2015026112A1 (ko) | 2015-02-26 |
Family
ID=52483844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/007620 WO2015026112A1 (ko) | 2013-08-19 | 2014-08-18 | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 혈액암 또는 암전이 억제용 조성물 |
Country Status (10)
Country | Link |
---|---|
US (3) | US10058527B2 (ko) |
EP (1) | EP3037092B1 (ko) |
JP (1) | JP6201054B2 (ko) |
KR (1) | KR101621851B1 (ko) |
CN (2) | CN105792822B (ko) |
AU (1) | AU2014309635B2 (ko) |
CA (1) | CA2921841C (ko) |
ES (1) | ES2779047T3 (ko) |
RU (1) | RU2632098C2 (ko) |
WO (1) | WO2015026112A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4051260A4 (en) * | 2019-10-28 | 2023-12-06 | Enzychem Lifesciences Corporation | METHODS AND COMPOSITIONS FOR TREATING CANCER |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2632098C2 (ru) * | 2013-08-19 | 2017-10-02 | Энзикем Лайфсайенсиз Корпорейшн | Композиция для подавления раковых заболеваний крови или метастазирования рака, содержащая в качестве активного ингредиента моноацетилдиглицеридное соединение |
WO2017082708A1 (ko) * | 2015-11-14 | 2017-05-18 | 주식회사 엔지켐생명과학 | 발작성 야간 혈색소뇨증의 치료 방법 |
WO2017082709A1 (ko) * | 2015-11-14 | 2017-05-18 | 주식회사 엔지켐생명과학 | 용혈성 요독 증후군의 치료 방법 |
KR101817552B1 (ko) * | 2016-10-13 | 2018-01-11 | 주식회사 엔지켐생명과학 | 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물 |
KR101836822B1 (ko) | 2016-10-17 | 2018-03-09 | 주식회사 엔지켐생명과학 | 모노아세틸디아실글리세롤 화합물을 함유하는 건선의 예방 또는 치료용 조성물 |
KR102076314B1 (ko) | 2018-07-16 | 2020-02-11 | (주) 에프엔지리서치 | 녹용에서 분리한 신규 화합물 및 이의 약학적 용도 |
WO2020144538A1 (en) * | 2019-01-07 | 2020-07-16 | Enzychem Lifesciences Corporation | Compositions and methods for modulating an inflammatory response |
CA3126887A1 (en) * | 2019-01-16 | 2020-07-23 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990044781A (ko) * | 1997-11-20 | 1999-06-25 | 윤종여 | 녹용 추출물을 함유하는 조혈모세포 및 혈소판 전구세포 증식촉진용 조성물 |
KR20050103259A (ko) * | 2004-04-24 | 2005-10-27 | 김상희 | 인터루킨-2 및 모노아세틸디글리세라이드-3을유효성분으로 함유하는 항암제 |
KR20060047447A (ko) * | 2004-04-24 | 2006-05-18 | 김상희 | 모노아세틸디아실글리세롤류 화합물을 유효성분으로함유하는 면역조절제, 항암제 및 건강식품 |
KR20070010841A (ko) * | 2005-07-20 | 2007-01-24 | 주식회사 엔지켐 | 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999026640A1 (en) | 1997-11-20 | 1999-06-03 | Bukwang Pharm. Ind. Co., Ltd. | Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes |
KR100646781B1 (ko) | 1999-10-15 | 2006-11-17 | 삼성전자주식회사 | 액정 표시 장치용 박막 트랜지스터 기판 및 그의 제조 방법 |
KR20050118057A (ko) * | 2004-04-24 | 2005-12-15 | 김상희 | 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품 |
RU2632098C2 (ru) * | 2013-08-19 | 2017-10-02 | Энзикем Лайфсайенсиз Корпорейшн | Композиция для подавления раковых заболеваний крови или метастазирования рака, содержащая в качестве активного ингредиента моноацетилдиглицеридное соединение |
-
2014
- 2014-08-18 RU RU2016109986A patent/RU2632098C2/ru active
- 2014-08-18 ES ES14838256T patent/ES2779047T3/es active Active
- 2014-08-18 JP JP2016536021A patent/JP6201054B2/ja not_active Expired - Fee Related
- 2014-08-18 CA CA2921841A patent/CA2921841C/en active Active
- 2014-08-18 KR KR1020140107233A patent/KR101621851B1/ko active IP Right Grant
- 2014-08-18 CN CN201480055291.2A patent/CN105792822B/zh not_active Expired - Fee Related
- 2014-08-18 CN CN201910459431.7A patent/CN110327324A/zh active Pending
- 2014-08-18 US US14/912,916 patent/US10058527B2/en active Active
- 2014-08-18 EP EP14838256.7A patent/EP3037092B1/en active Active
- 2014-08-18 WO PCT/KR2014/007620 patent/WO2015026112A1/ko active Application Filing
- 2014-08-18 AU AU2014309635A patent/AU2014309635B2/en not_active Ceased
-
2018
- 2018-07-25 US US16/045,617 patent/US10857119B2/en active Active
-
2020
- 2020-05-28 US US16/886,280 patent/US20200330421A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990044781A (ko) * | 1997-11-20 | 1999-06-25 | 윤종여 | 녹용 추출물을 함유하는 조혈모세포 및 혈소판 전구세포 증식촉진용 조성물 |
KR20050103259A (ko) * | 2004-04-24 | 2005-10-27 | 김상희 | 인터루킨-2 및 모노아세틸디글리세라이드-3을유효성분으로 함유하는 항암제 |
KR20060047447A (ko) * | 2004-04-24 | 2006-05-18 | 김상희 | 모노아세틸디아실글리세롤류 화합물을 유효성분으로함유하는 면역조절제, 항암제 및 건강식품 |
KR20070010841A (ko) * | 2005-07-20 | 2007-01-24 | 주식회사 엔지켐 | 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체 |
KR100789323B1 (ko) | 2005-07-20 | 2007-12-28 | 주식회사 엔지켐 | 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체 |
Non-Patent Citations (1)
Title |
---|
KIM, MYUNG-HWAN ET AL.: "EC -18, a synthetic monoacetyldiacylglyceride, inhibits hematogenous metastasis of KIGB-5 biliary cancer cell in hamster model", JOURNAL OF KOREAN MEDICAL SCIENCE, vol. 24, 2009, pages 474 - 480, XP055321285 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4051260A4 (en) * | 2019-10-28 | 2023-12-06 | Enzychem Lifesciences Corporation | METHODS AND COMPOSITIONS FOR TREATING CANCER |
Also Published As
Publication number | Publication date |
---|---|
EP3037092B1 (en) | 2020-01-01 |
EP3037092A1 (en) | 2016-06-29 |
EP3037092A4 (en) | 2017-04-26 |
KR101621851B1 (ko) | 2016-05-31 |
RU2016109986A (ru) | 2017-09-26 |
CA2921841C (en) | 2018-06-19 |
US20190022047A1 (en) | 2019-01-24 |
US10058527B2 (en) | 2018-08-28 |
JP2016528277A (ja) | 2016-09-15 |
US20160256428A1 (en) | 2016-09-08 |
ES2779047T3 (es) | 2020-08-13 |
CN105792822A (zh) | 2016-07-20 |
CN110327324A (zh) | 2019-10-15 |
CA2921841A1 (en) | 2015-02-26 |
CN105792822B (zh) | 2019-06-21 |
AU2014309635A1 (en) | 2016-03-10 |
KR20150021464A (ko) | 2015-03-02 |
US10857119B2 (en) | 2020-12-08 |
RU2632098C2 (ru) | 2017-10-02 |
JP6201054B2 (ja) | 2017-09-20 |
AU2014309635B2 (en) | 2017-04-06 |
US20200330421A1 (en) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015026112A1 (ko) | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 혈액암 또는 암전이 억제용 조성물 | |
KR101621856B1 (ko) | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
WO2018070854A2 (ko) | 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물 | |
KR20190112492A (ko) | 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제 | |
JP2021169465A (ja) | モノアセチルジアシルグリセロール化合物を含有する乾癬の予防または治療用組成物 | |
KR20190016737A (ko) | 모노아세틸디아실글리세롤 화합물을 함유하는 급성 폐손상의 예방 또는 치료용 조성물 | |
WO2017082709A1 (ko) | 용혈성 요독 증후군의 치료 방법 | |
KR20150011875A (ko) | 신규 트리테르펜 글루코사이드 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 약학조성물 | |
WO2024005289A1 (ko) | 테노포비르 알라페나미드를 포함하는 비알콜성 지방간염 예방, 개선 또는 치료용 조성물 | |
WO2024080420A1 (ko) | 진세노사이드 rh2 및 진세노사이드 rg5를 유효성분으로 함유하는 간암 예방 및 치료용 조성물 | |
WO2024063545A1 (ko) | 락토바실러스 플란타룸 균주를 포함하는 장내 대사산물 조성의 개선을 위한 조성물 | |
KR20190018317A (ko) | 모노아세틸디아실글리세롤 화합물을 함유하는 슈도모나스 속 미생물 감염증의 예방 또는 치료용 조성물 | |
WO2022235050A1 (ko) | 지유 추출물을 유효성분으로 함유하는 종양증식 억제용 조성물 | |
KR20240023365A (ko) | 지의류 내생 곰팡이 추출물 및 이로부터 분리된 화합물을 포함하는 면역 항암용 조성물 | |
KR101558946B1 (ko) | 팔각회향 추출물 또는 이의 분획물을 포함하는 암 전이 억제 또는 암 예방용 조성물 | |
WO2017222252A1 (ko) | 텔렉타디엄 동나이엔스 추출물을 유효성분으로 하는 대장암 예방 또는 치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14838256 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2921841 Country of ref document: CA Ref document number: 2016536021 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14912916 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014309635 Country of ref document: AU Date of ref document: 20140818 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014838256 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016109986 Country of ref document: RU Kind code of ref document: A |